J
Jonas Hugosson
Researcher at University of Gothenburg
Publications - 277
Citations - 17700
Jonas Hugosson is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 56, co-authored 255 publications receiving 16010 citations. Previous affiliations of Jonas Hugosson include Erasmus University Medical Center & University of Tampere.
Papers
More filters
Journal ArticleDOI
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,Alvaro Paez,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Sigrid Carlsson,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Paula Kujala,Bert G. Blijenberg,Ulf-Håkan Stenman,Andreas R. Huber,Kimmo Taari,Matti Hakama,Sue Moss,Harry J. de Koning,Anssi Auvinen +27 more
TL;DR: Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.
Journal ArticleDOI
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
Jonas Hugosson,Sigrid Carlsson,Gunnar Aus,Svante Bergdahl,Ali Khatami,Pär Lodding,Carl-Gustaf Pihl,Johan Stranne,Erik Holmberg,Hans Lilja,Hans Lilja +10 more
TL;DR: It is shown that prostate cancer mortality was reduced almost by half over 14 years, however, the risk of over-diagnosis is substantial and the number needed to treat is at least as high as in breast-cancer screening programmes.
Journal ArticleDOI
Quality-of-life effects of prostate-specific antigen screening.
Eveline A.M. Heijnsdijk,Elisabeth M. Wever,Anssi Auvinen,Jonas Hugosson,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Arnauld Villers,Alvaro Paez,Sue Moss,Marco Zappa,Teuvo L.J. Tammela,Tuukka Mäkinen,Sigrid Carlsson,Ida J. Korfage,Marie-Louise Essink-Bot,Suzie J. Otto,Gerrit Draisma,Chris H. Bangma,Monique J. Roobol,Fritz H. Schröder,Harry J. de Koning +21 more
TL;DR: The benefit of PSA screening was diminished by loss of QALYs owing to postdiagnosis long-term effects, and longer follow-up data from both the ERSPC and quality-of-life analyses are essential before universal recommendations regarding screening can be made.